Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

A federal judge tripled damages against the pharmacy benefits manager after finding it encouraged inflated Medicare drug claims and underpaid pharmacies.

CVS Caremark Ordered to Pay $290 Million in False Claims Act Whistleblower Case

Podcasts

This episode of Pharma Pulse covers the White House–EU agreement on pharmaceutical tariffs, Johnson & Johnson’s $2 billion expansion of its North Carolina manufacturing site, and a new federal rule requiring e-prescribing and prior authorization tools in certified EHR systems.

Pharma Pulse: Pharma Tariffs Take Shape, J&J Invests $2 Billion in US Manufacturing, and New EHR Rule Targets Prior Authorization

The new framework, set to take effect September 1, limits tariffs on pharmaceutical imports to 15% but follows months of shifting proposals, including threats of tariffs as high as 250%.

White House and EU Finalize Trade Deal With 15% Cap on Pharma Tariffs

The company will be heavily investing over the next decade to build a new biopharmaceutical facility in Holly Springs, NC, creating 120 jobs and reinforcing its $55 billion pledge to strengthen US manufacturing, R&D, and innovation.

Johnson & Johnson Commits $2 Billion to North Carolina Manufacturing Expansion

This episode of Pharma Pulse covers Catalent’s decision to cut 350 jobs at its Baltimore gene therapy site, new data showing rising adoption of digital tools for glycemic control in type 1 diabetes, and research linking severe childhood COVID-19 to heightened cardiovascular risk later in life.

Pharma Pulse: Catalent Layoffs, Diabetes Tech Adoption, and Long-Term Heart Risks from Childhood COVID-19

Videos

In the third part of his Pharma Commerce video interview, Dave Malenfant, a healthcare supply chain expert, discusses how predictive analytics, AI, and automation are streamlining US pharmaceutical manufacturing—cutting overhead, boosting efficiency, and enhancing safety.

New Technologies Drive Down Pharma Manufacturing Costs in the United States

The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.

Catalent to Lay Off 350 Workers at Baltimore Gene Therapy Plant 

This episode of Pharma Pulse explores a Battelle–Aprecia partnership with HHS and DARPA to accelerate on-demand drug manufacturing, a multi-billion-dollar Merck KGaA–Skyhawk collaboration to advance RNA therapies in neurology, and how pharmacist-led telehealth is improving diabetes care during emergencies.

Pharma Pulse: Agile Drug Manufacturing Advances, Merck–Skyhawk RNA Deal, and Telehealth Expands Pharmacists’ Role

The EQUIP-A-Pharma program will combine Battelle’s synthesis platform and Aprecia’s 3D printing technology to produce APIs and finished drugs at the same site, aiming to strengthen US pharma supply resilience and support essential medicines.

Battelle and Aprecia Partner With HHS and DARPA to Advance Agile Drug Manufacturing

Payer-level reporting should do more than track performance—it must guide strategy, focus resources, and drive measurable brand impact.

Business and Finance